1. |
中华医学会儿科学分会眼科学组. 早产儿视网膜病变治疗规范专家共识[J]. 中华眼底病杂志, 2022, 38(1): 10-13. DOI: 10.3760/cma.j.cn511434-20211119-00647.Ophthalmology Group of Pediatrics Society of Chinese Medical Association. Expert consensus on the treatment of retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2022, 38(1): 10-13. DOI: 10.3760/cma.j.cn511434-20211119-00647.
|
2. |
Blencowe H, Lawn JE, Vazquez T, et al. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010[J]. Pediatr Res, 2013, 74(1): 35-49. DOI: 10.1038/pr.2013.205.
|
3. |
Wang L, Li M, Zhu J, et al. Clinical features of spontaneous regression of retinopathy of prematurity in China: a 5-year retrospective case series[J/OL]. Front Med (Lausanne), 2021, 8: 731421[2021-08-31]. https://pubmed.ncbi.nlm.nih.gov/34532335/. DOI: 10.3389/fmed.2021.731421.
|
4. |
Chiang MF, Quinn GE, Fielder AR, et al. International classification of retinopathy of prematurity, third edition[J]. Ophthalmology, 2021, 128(10): 51-68. DOI: 10.1016/j.ophtha.2021.05.031.
|
5. |
王亮, 张自峰, 李曼红, 等. 早产儿视网膜病变的自然退行[J]. 中华眼科杂志, 2021, 57(2): 150-155. DOI: 10.3760/cma.j.cn112142-20200331-00231.Wang L, Zhang ZF, Li MH, et al. Spontaneous regression of the retinopathy of prematurity[J]. Chin J Ophthalmol, 2021, 57(2): 150-155. DOI: 10.3760/cma.j.cn112142-20200331-00231.
|
6. |
武雷, 李曼红, 张自峰, 等. 荧光素眼底血管造影在早产儿视网膜病变中的应用[J]. 国际眼科纵览, 2020, 44(5): 340-345. DOI: 10.3760/cma.j.issn.1673-5803.2020.05.008.Wu L, Li MH, Zhang ZF, et al. Application of fundus fluorescein angiography on retinopathy of prematurity[J]. Int Rev Ophthalmol, 2020, 44(5): 340-345. DOI: 10.3760/cma.j.issn.1673-5803.2020.05.008.
|
7. |
Ni YQ, Huang X, Xue K, et al. Natural involution of acute retinopathy of prematurity not requiring treatment: factors associated with the time course of involution[J]. Invest Ophthalmol Vis Sci, 2014, 55(5): 3165-3170. DOI: 10.1167/iovs.13-13744.
|
8. |
中华医学会眼科学分会眼底病学组. 中国早产儿视网膜病变筛查指南(2014年)[J]. 中华眼科杂志, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.Ophthalmology Group of Chinese Medical Association Ophthalmology Branch. Guidelines for screening of retinopathy of prematurity in China (2014)[J]. Chin J Ophthalmol, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.
|
9. |
中华医学会儿科学分会眼科学组. 中国婴幼儿全身麻醉下眼病检查专家共识(2022年)[J]. 中华眼科杂志, 2022, 58(3): 169-175. DOI: 10.3760/cma.j.cn112142-20210501-00205.Ophthalmology Group of Chinese Pediatric Society of Chinese Medical Association. Chinese expert consensus on eye examination under general anesthesia for infants (2022)[J]. Chin J Ophthalmol, 2022, 58(3): 169-175. DOI: 10.3760/cma.j.cn112142-20210501-00205.
|
10. |
Lorenz B, Stieger K, Jager M, et al. Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study[J]. Retina, 2017, 37(1): 97-111. DOI: 10.1097/IAE.0000000000001126.
|
11. |
Blair MP, Shapiro MJ, Hartnett ME. Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children[J]. J AAPOS, 2012, 16(3): 234-237. DOI: 10.1016/j.jaapos.2011.12.157.
|
12. |
Hamad AE, Moinuddin O, Blair MP, et al. Late-onset retinal findings and complications in untreated retinopathy of prematurity[J]. Ophthalmol Retina, 2020, 4(6): 602-612. DOI: 10.1016/j.oret.2019.12.015.
|
13. |
Lepore D, Quinn GE, Molle F, et al. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser[J]. Ophthalmology, 2018, 125(2): 218-226. DOI: 10.1016/j.ophtha.2017.08.005.
|
14. |
Lepore D, Molle F, Pagliara MM, et al. Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity[J]. Ophthalmology, 2011, 118(1): 168-175. DOI: 10.1016/j.ophtha.2010.04.021.
|
15. |
Mansukhani SA, Hutchinson AK, Neustein R, et al. Fluorescein angiography in retinopathy of prematurity: comparison of infants treated with bevacizumab to those with spontaneous regression[J]. Ophthalmol Retina, 2019, 3(5): 436-443. DOI: 10.1016/j.oret.2019.01.016.
|
16. |
Hughes S, Gardiner T, Baxter L, et al. Changes in pericytes and smooth muscle cells in the kitten model of retinopathy of prematurity: implications for plus disease[J]. Invest Ophthalmol Vis Sci, 2007, 48(3): 1368-1379. DOI: 10.1167/iovs.06-0850.
|
17. |
Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, et al. Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab[J]. Ophthalmic Surg Lasers Imaging Retina, 2016, 47(3): 280-283. DOI: 10.3928/23258160-20160229-12.
|
18. |
Vural A, Demirayak B, Ozbas M, et al. Comparison of fluorescein angiography findings in stage 3 retinopathy of prematurity in zone Ⅱ treated with or without anti-VEGF[J/OL]. Eur J Ophthalmol, 2022: 1369443762[2022-02-22]. https://pubmed.ncbi.nlm.nih.gov/35191353/. DOI: 10.1177/11206721221076691.
|
19. |
李慧林, 张国明, 张福燕, 等. 退行期早产儿视网膜病变广角荧光素眼底血管造影特征[J]. 中华眼底病杂志, 2016, 32(4): 430-431. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.020.Li HL, Zhang GM, Zhang FY, et al. Characteristics of wide-field fluorescein fundus angiography in degenerative retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2016, 32(4): 430-431. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.020.
|
20. |
Vural A, Ekinci DY, Onur IU, et al. Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression[J]. Int Ophthalmol, 2019, 39(10): 2267-2274. DOI: 10.1007/s10792-018-01064-7.
|